Tema Heart & Health ETF (NASDAQ:HRTS) Short Interest Up 151.2% in April

Tema Heart & Health ETF (NASDAQ:HRTS) was the target of a significant increase in short interest in the month of April. As of April 30th, there was short interest totaling 1,595 shares, an increase of 151.2% from the April 15th total of 635 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily volume of 3,009 shares, the days-to-cover ratio is presently 0.5 days.

Tema Heart & Health ETF Trading Down 1.6%

HRTS traded down $0.55 during midday trading on Friday, reaching $33.34. The company’s stock had a trading volume of 1,507 shares, compared to its average volume of 6,485. The firm has a market capitalization of $49.68 million, a price-to-earnings ratio of 22.06 and a beta of 0.70. Tema Heart & Health ETF has a 1 year low of $26.78 and a 1 year high of $36.65. The stock’s 50-day moving average is $33.72 and its 200-day moving average is $34.66.

Institutional Investors Weigh In On Tema Heart & Health ETF

A number of hedge funds and other institutional investors have recently bought and sold shares of HRTS. Kestra Advisory Services LLC purchased a new stake in Tema Heart & Health ETF in the fourth quarter worth about $27,000. JPMorgan Chase & Co. purchased a new stake in shares of Tema Heart & Health ETF during the second quarter valued at approximately $63,000. Citadel Advisors LLC purchased a new stake in shares of Tema Heart & Health ETF during the third quarter valued at approximately $243,000. Brookstone Capital Management purchased a new stake in Tema Heart & Health ETF during the 4th quarter valued at $364,000. Finally, Jane Street Group LLC boosted its stake in Tema Heart & Health ETF by 9.4% during the 2nd quarter. Jane Street Group LLC now owns 37,164 shares of the company’s stock valued at $1,062,000 after purchasing an additional 3,202 shares during the last quarter.

About Tema Heart & Health ETF

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.